- Published at
- by physicianonfire.com
mixed
mixed
News for Synlogic, Inc. (SYBX)
- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
positivepositiveSynlogic's head of finance Mary Beth Dooley sells $110 in stock By Investing.com
Synlogic's head of finance Mary Beth Dooley sells $110 in stock- Published at
- by globenewswire.com
mixedmixedOxygen Scavenger Market Set to Reach USD 8.2 Billion by 2032 | Innovations and Demand for Shelf-life Extension Drive Market Growth | Research by SNS Insider
The Oxygen Scavenger growth is primarily fueled by the increasing demand for oxygen scavengers in food packaging, and pharmaceuticals, aimed at enhancing...- Published at
- by globenewswire.com
mixedmixedEliem Therapeutics Reports Second Quarter Financial Results
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to...- Published at
- by globenewswire.com
positivepositiveSynlogic Reports Second Quarter 2024 Financial Results
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform...- Published at
- by investing.com
positivepositive- Published at
- by globenewswire.com
mixedmixedXilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...- Published at
- by benzinga.com
positivepositiveSynlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates - Barinthus Biotherapeutics (NASDAQ:BRNS), Synlogic (NASDAQ:SYBX)
Synlogic, Inc. (NASDAQ: SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.- Published at
- by zacks.com
positivepositiveSynlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by globenewswire.com
neutralneutralSynlogic Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform...- Published at
- by globenewswire.com
positivepositiveSynlogic Adopts Limited Duration Stockholders Rights Plan
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process...- Published at
- by investing.com
mixedmixedU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.14% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.14%- Published at
- by benzinga.com
mixedmixedWhy Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday’s Mid-Day Session - Take-Two Interactive (NASDAQ:TTWO)
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.- Published at
- by benzinga.com
positivepositiveS&P 500 Tops 5,000; PepsiCo Posts Upbeat Earnings - BioXcel Therapeutics (NASDAQ:BTAI), NanoString Technologies (NASDAQ:NSTG)
U.S. stocks traded mixed this morning, with the S&P 500 topping the 5,000 mark on Friday. Following the market opening Friday, the Dow traded down 0.05% to 38,706.33 while the NASDAQ rose 0.32% to 15,844.63. The S&P 500 also rose, gaining, 0.11% to 5,003.51.- Published at
- by globenewswire.com
mixedmixed- Published at
- by prnewswire.com
mixedmixedUrea Cycle Disorder Treatment Market to grow by USD 235.5 million from 2022-2027 | North America to account for 36% of market growth - Technavio
/PRNewswire/ -- The urea cycle disorder treatment market size is expected to grow by USD 235.5 million from 2022 to 2027. In addition, the momentum of the...- Published at
- by prnewswire.com
mixedmixedGlobal Human Microbiome Market Report 2023: Sector is Projected to Reach $1.7 Billion by 2029 at a CAGR of 36.1%
/PRNewswire/ -- The "Global Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer,...- Published at
- by prnewswire.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedGlobal Gout Therapeutics Market Size To Grow USD 7.1 Billion By 2032 | CAGR of 12.7%
The Global Gout Therapeutics Market Size was valued at USD 2.1 Billion in 2022 and the worldwide gout therapeutics market Size is expected to reach USD 7.1...